Market
Impact of Catalent acquisition on Novo Nordisk's diabetes market share by end of 2025?
2
Resolution / Starting Odds
Significantly increase • 25%
Slightly increase • 25%
No change • 25%
Decrease • 25%
Market share reports from reputable industry analysts or financial news outlets
Story
Novo Nordisk ($500B) Acquires Catalent for $16.5B to Boost Production of Wegovy, Ozempic
Dec 16, 2024, 04:02 AM
Novo Nordisk, valued at over $500 billion, is set to close its $16.5 billion acquisition of Catalent, a leading contract drug manufacturer, after the U.S. Federal Trade Commission (FTC) declined to challenge the deal. The acquisition, which also involves Novo Holdings taking over Catalent and Novo Nordisk acquiring three manufacturing sites from Novo Holdings, aims to address production capacity issues for Novo Nordisk's popular weight loss and diabetes drugs, Ozempic and Wegovy. Catalent, a subcontractor that already helps manufacture Wegovy, has been an attractive target due to its role in the pharmaceutical supply chain. The deal has received approval from both the European Commission and the FTC, following concerns about potential impacts on competition in the pharmaceutical industry. In addition to the acquisition, Novo Nordisk announced an investment of DKK 8.5 billion ($1.2 billion) in a new production facility in Odense, Denmark, to further expand its manufacturing capabilities for rare disease drugs.
View original story
Similar markets
Increase by more than 5% • 25%
Increase by 1-5% • 25%
Decrease • 25%
No significant change • 25%
Growth below 5% • 25%
No growth • 25%
Growth above 10% • 25%
Growth 5-10% • 25%
Top 20 • 25%
Top 5 • 25%
Top 10 • 25%
Below Top 20 • 25%
Eli Lilly > 60% • 25%
Novo Nordisk 40-60% • 25%
Novo Nordisk > 60% • 25%
Eli Lilly 40-60% • 25%
Less than 30% • 25%
More than 50% • 25%
40% to 50% • 25%
30% to 40% • 25%
Focus on improving CagriSema • 25%
Pursue mergers or acquisitions • 25%
Increase investment in marketing existing drugs • 25%
Develop a new obesity drug • 25%